HPV knowledge and acceptance of HPV vaccination among Men who have Sex with Men (MSM) in Germany: A cross-sectional study

HPV knowledge and acceptance of HPV vaccination among Men who have Sex with Men (MSM) in Germany: A cross-sectional study - HPV Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025510

Enrollment

1000

Registered

2023-09-22

Start date

2023-10-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No disease is investigated in the study but the level of knowledge about HPV as well as the acceptance of HPV vaccination among MSM, eConsent, digital data collection.

Interventions

Group 1: Subject is MSM, identified by the physician (see chapter 6.1.1) Subject is between =18 and =45 years of age Permanent resident in Germany for at least three years Signed ICF including data pr

Eligibility

Sex/Gender

Male

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Subject is MSM, identified by the physician (see chapter 6.1.1) Permanent resident in Germany for at least three years Signed ICF including data protection consent Subject is insured by a German health insurance company

Exclusion criteria

Exclusion criteria: Subject is not able to read and understand the questionnaire in German or English.

Design outcomes

Primary

Measure	Time frame
HPV and HPV vaccine knowledge in MSM in Germany: The primary outcome to describe the knowledge of HPV will be the assessed by 20 statements. To avoid missing data within the scale questions, the participant needs to choose one of the three answer options for each single question in order to proceed with the next question of the questionnaire Acceptance of HPV vaccination in MSM in Germany: The primary outcome to describe the knowledge of HPV vaccination will be the assessed by five statements. To avoid missing data within the scale questions, the participant needs to choose one of the three answer options for each single question in order to proceed with the questionnaire. Patients who have not heard of either HPV or HPV vaccination before participation in this study will not proceed with the knowledge of HPV vaccination assessment. Accordingly, they will not be included in the sum-score, but the percentage of these participants will be derived and reported separately as this reflects the complete absence of HPV vaccination awareness	—

Measure

Time frame

HPV and HPV vaccine knowledge in MSM in Germany: The primary outcome to describe the knowledge of HPV will be the assessed by 20 statements. To avoid missing data within the scale questions, the participant needs to choose one of the three answer options for each single question in order to proceed with the next question of the questionnaire Acceptance of HPV vaccination in MSM in Germany: The primary outcome to describe the knowledge of HPV vaccination will be the assessed by five statements. To avoid missing data within the scale questions, the participant needs to choose one of the three answer options for each single question in order to proceed with the questionnaire. Patients who have not heard of either HPV or HPV vaccination before participation in this study will not proceed with the knowledge of HPV vaccination assessment. Accordingly, they will not be included in the sum-score, but the percentage of these participants will be derived and reported separately as this reflects the complete absence of HPV vaccination awareness

—

Secondary

Measure	Time frame
HPV vaccination uptake in MSM in Germany Knowledge of HPV and HPV vaccination, acceptance of HPV vaccination, and HPV vaccine uptake in = 18- = 26 and = 27- = 45 years old MSM as well as HIV+, HIV- and not tested MSM	—

Countries

Germany

Contacts

Public ContactCornelia Wähner

MSD Sharp & Dohme GmbH

cornelia.waehner@msd.de+49 (0) 89 460 10 10

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026